Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Impact of preventing exacerbations on deterioration of health status in COPD

S. Spencer, P.M.A. Calverley, P.S. Burge, P.W. Jones
European Respiratory Journal 2004 23: 698-702; DOI: 10.1183/09031936.04.00121404
S. Spencer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P.M.A. Calverley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P.S. Burge
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P.W. Jones
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Figures

  • Tables
  • Fig. 1.—
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.—

    Baseline St Georges Respiratory Questionnaire (SGRQ) scores by exacerbation category. Data are presented as mean and 95% confidence intervals (bars). Baseline SGRQ score was missing for six infrequent exacerbators and for five frequent exacerbators. High score indicates worse health. #: p=0.002; ¶: p=0.03. None, n=91; infrequent, n=279; frequent, n=230.

  • Fig. 2.—
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.—

    Deterioration in St Georges Respiratory Questionnaire (SGRQ) total score by exacerbation category. Data are presented as mean and 95% confidence intervals (bars). Higher score indicates faster deterioration in health. #: p<0.0001; ¶: p=0.004. None, n=91; infrequent, n=285; frequent, n=235.

Tables

  • Figures
  • Table 1—

    Baseline characteristics by exacerbation status: exacerbators versus nonexacerbators

    Number of exacerbationsFrequency of exacerbations
    None≥1p-value<1.65·yr−1>1.65·yr−1p-value
    Subjects n93520291286
    Sex M %86730.00972740.7
    Age yrs65±764±70.0663±764±70.05
    Current smokers %52480.648480.9
    SGRQ total score42±1750±17<0.000148±1852±150.03
    FEV1 % pred55±1549±150.00153±1545±13<0.0001
    • Data are presented as mean±sd unless otherwise stated

    • Mean exacerbation rate in patients with exacerbations >0 and <1.65·yr−1 was 0.9·yr−1, and in patients with exacerbations >1.65·yr−1 was 2.8·yr−1

    • M: male

    • SGRQ: St Georges Respiratory Questionnaire

    • FEV1: forced expiratory volume in one second

  • Table 2—

    Effect of treatment and exacerbation frequency on change in St Georges Respiratory Questionnaire (SGRQ) score

    SGRQ score units·yr−1p-value
    Exacerbation frequency
     None2.00.0003
     Infrequent2.4
     Frequent2.9
    Treatment
     FP2.20.02
     Placebo2.6
    • Data are presented as mean or as p-value

    • FP: fluticasone proprionate

  • Table 3—

    Relationship between deterioration in St Georges Respiratory Questionnaire (SGRQ) score, exacerbation group and treatment

    SGRQ score units·yr−1p-value
    Exacerbation group
     None2.00.0003
     Infrequent2.4
     Frequent2.9
    Treatment
     FP2.30.1
     Placebo2.5
    Exacerbation group * treatment0.2
    • Data are presented as mean or p-value

    • FP: fluticasone proprionate

  • Table 4—

    Relationship between deterioration in St Georges Respiratory Questionnaire (SGRQ) score, forced expiratory volume in one second (FEV1) decline and treatment

    FEV1 decline mL·yr−1·1 unit SGRQ−1SGRQ score mean units·yr−1p-value
    FEV1 decline rate−6.3<0.0001
    Treatment
     FP2.30.02
     Placebo2.7
    FEV1 decline * treatment0.2
    • FP: fluticasone proprionate

PreviousNext
Back to top
View this article with LENS
Vol 23 Issue 5 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Impact of preventing exacerbations on deterioration of health status in COPD
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Impact of preventing exacerbations on deterioration of health status in COPD
S. Spencer, P.M.A. Calverley, P.S. Burge, P.W. Jones
European Respiratory Journal May 2004, 23 (5) 698-702; DOI: 10.1183/09031936.04.00121404

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Impact of preventing exacerbations on deterioration of health status in COPD
S. Spencer, P.M.A. Calverley, P.S. Burge, P.W. Jones
European Respiratory Journal May 2004, 23 (5) 698-702; DOI: 10.1183/09031936.04.00121404
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Novel strategy to identify genetic risk factors for COPD severity: a genetic isolate
  • Calculating gambling odds and lung ages for smokers
  • Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study
Show more Original Articles: COPD

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society